FIA
XERS icon

FNY Investment Advisers’s Xeris Biopharma Holdings XERS Stock Holding History

FNY Investment Advisers’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,500
Closed -$63K – 1207
2025
Q1 		$63K Buy
+11,500
New +$46.4K 0.04% 266
2022
Q1 		– Sell
-49,088
Closed -$143K – 932
2021
Q4 		$143K Buy
+49,088
New +$106K 0.08% 180

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FNY Investment Advisers's XERS Position: Q2 2025 in Review

FNY Investment Advisers sold out of Xeris Biopharma Holdings (XERS) in Q2 2025, closing a stake of 11,500 shares — an estimated $63K sold.

FNY Investment Advisers first reported a position in XERS in Q4 2021 and held it in 2 quarters. The position peaked at $143K in Q4 2021. 200 funds tracked by Wall St. Rank hold XERS as of Q2 2025.

  • FNY Investment Advisers reported no remaining Xeris Biopharma Holdings position as of Q2 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 11,500 Xeris Biopharma Holdings shares in Q2 2025, an estimated $63K.
  • FNY Investment Advisers first reported a position in Xeris Biopharma Holdings in Q4 2021 and held it in 2 quarters.
  • FNY Investment Advisers's Xeris Biopharma Holdings position peaked at $143K in Q4 2021.
  • 200 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2025.

Based on FNY Investment Advisers's 13F filing for Q2 2025, filed 30 Jul 2025.